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Abstract Hereditary non-polyposis colorectal cancer
(HNPCC) is an autosomal, dominantly inherited, colo-
rectal cancer (CRC) predisposition syndrome caused by
germline mutations in DNA mismatch repair (MMR)
genes, predominantlyMLH1 andMSH2. Thus far, only
limited data exist on the occurrence of genetic antici-
pation in HNPCC, i.e. the earlier age at diagnosis of
CRC in successive generations. Performing nonpara-
metric distribution-free statistical analyses, we investi-
gated 55 parent–child pairs who had been diagnosed
with CRC and who came from 21 Swiss HNPCC fam-
ilies with characterised MMR germline mutation (15 in
MLH1 and 6 in MSH2). The overall median age at
diagnosis was 43 years, with an interquartile range
(IQR) of 14 and incidence ages ranging from 18 to
62 years. Descendants of HNPCC patients (median age
at diagnosis 39 years, IQR=12) were found to be
diagnosed with CRC signiﬁcantly earlier than their
parents (47 years, IQR=10), with the median of the
paired age diﬀerence amounting to 8 years (IQR=15;
P<0.0001). Birth cohort eﬀects could be excluded, since
the same, statistically signiﬁcant, age diﬀerence was also
observed in the oldest oﬀspring birth cohort (birth year
<1916; P=0.01). Genetic anticipation appeared to be
more pronounced when the disease allele was transmit-
ted through the father than through the mother (median
age diﬀerence 11 vs. 4 years, respectively; both P<0.01).
If conﬁrmed in larger, ideally prospective studies, these
results may have important implications for genetic
counselling and clinical management of HNPCC
families.
Introduction
Hereditary non-polyposis colorectal cancer (HNPCC) is
an autosomal, dominantly inherited, colorectal cancer
(CRC) predisposition syndrome, exhibiting high pene-
trance (80%–85%) and accounting for 2%–10% of the
total CRC burden (Lynch and de la Chapelle 1999).
HNPCC patients typically present with, mostly right-
sided, CRC at an early age (mean age 45 years) and
often develop synchronous or metachronous CRC. In
addition to CRC, the tumour spectrum includes cancers
of the endometrium, stomach, small bowel, ovary, ure-
ter/renal pelvis, brain, hepatobiliary tract and skin.
HNPCC is caused by mutations in DNA mismatch re-
pair (MMR) genes (MSH2, MLH1, MSH6, PMS2),
with MLH1 and MSH2 accounting for more than 90%
of all germline mutations identiﬁed. Following inacti-
vation of the wild-type allele in the tumour, MMR
deﬁciency ensues, leading to genetic instability as
exempliﬁed by the occurrence of microsatellite instabil-
ity caused by replication errors at short repetitive DNA
sequences. The disease shows considerable interfamilial
and intrafamilial phenotypic heterogeneity among
MLH1/MSH2 mutation carriers. Despite harbouring
identical MMR gene mutations, disease severity and age
at diagnosis often vary signiﬁcantly between family
members. In this context, genetic anticipation, a ‘‘phe-
nomenon in which the age of onset of a disorder is re-
duced and/or the severity of the phenotype is increased
in successive generations’’ (Strachan and Read 1999),
has been postulated to occur in HNPCC. Thus far, only
limited and controversial data are available on this issue,
ranging from single case reports to a few systematic
investigations in HNPCC families (Menko et al. 1993;
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Rodriguez-Bigas et al. 1996; Tsai et al. 1997; Vasen et al.
1994). In this study, we have examined 21 Swiss HNPCC
kindreds with identiﬁed MLH1 or MSH2 germline
mutations for the occurrence of genetic anticipation with
regard to the age at diagnosis of CRC in parents and
their descendants (ﬁrst-degree kinship).
Subjects and methods
Out of 46 Swiss HNPCC families with an identiﬁed
MMR gene mutation in MLH1 or MSH2, registered
between 1990 and 2001 either at the Research Group
Human Genetics, Division of Medical Genetics, Depart-
ment of Clinical and Biological Sciences, Basel, or at the
Unit of Genetics, Institut Central des Hoˆpitaux Valaisans,
Sion, Switzerland, 26 (57%) unrelated families were
considered suitable for the study. Complete phenotypic
information was available from medical and histopatho-
logical records regarding gender, year of birth, age at
diagnosis, tumour type and the occurrence of additional
(extracolonic) tumours.
The 26 families harboured either a pathogenic
MLH1 (n=18) or an MSH2 (n=8) germline mutation.
Out of the 126 individual patients, 91 parent–child
pairs (PCPs) were created, each consisting of an af-
fected parent and an aﬀected child. Twenty-two parents
had more than one child (range: 2–5 children) and 14
descendants also had aﬀected children included in this
study. In 145 (79.7%) MLH1/MSH2 known or oblig-
atory mutation carriers, the ﬁrst tumour diagnosed was
colorectal, compared with 37 (20.3%) patients with an
extracolonic tumour. For the study, only PCPs with
children and parents aﬀected with CRC (21 families;
n=55) were analysed. Based on the available clinical
records, there was no indication that some of the pa-
tients participated in regular endoscopic surveillance
programmes prior to the cancer diagnosis. The PCPs
were treated as related data for the statistical analysis.
Written informed consent was obtained from all indi-
viduals alive.
Statistical analysis
Nonparametric distribution-free tools were applied for
statistical analysis. Related data were compared by
applying the Wilcoxon matched-pairs signed-ranks test
(referred to as paired Wilcoxon test). Independent data
were compared with the Mann–Whitney U test. The
disproportions of gender frequencies were analysed with
the Binomial test. The median and the interquartile
range (IQR) were used instead of the mean and the
standard deviation, respectively. The signiﬁcance level
was set to £ 0.05 (5%). All statistical tests were applied
Fig. 1 a Overall median age at
diagnosis, grouped in 5-year age
classes, comparing parents
(black bars) with their
descendants (grey bars) from 21
HNPCC kindreds with
identiﬁed MLH1 or MSH2
germline mutations. b Box plot
(including median and 10th,
25th, 75th and 90th percentile)
of the paired age diﬀerence
(years) between parents and
descendants, grouped according
to parental age at diagnosis of
colorectal cancer (<40 below
age 40, 40–50 between age 40
and 50, >50 above age 50)
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in their two-sided form. The software-packages used for
the statistical analysis were ‘‘RS/1’’ (Research System 1),
Version 6.1 (Brooks Automation), and ‘‘StatXact’’,
Version 4 (Cytel Software Corporation).
Results
To assess the occurrence of genetic anticipation in
HNPCC, 55 PCPs aﬀected with CRC and coming from
21 Swiss HNPCC kindreds with identiﬁed MLH1
(n=15) or MSH2 (n=6) germline mutations were
examined. The PCPs encompassed 52 (62.7%) male and
31 (37.3%) female known or obligatory mutation car-
riers. Following CRC diagnosis, 24 (28.9%) patients
also developed metachronous cancers (range 1–4 tu-
mours) encompassing those of the colorectum (n=15;
62.5%), small intestine (n=2; 8.3%), stomach (n=1;
4.2%) and other sites (n=6; 25%). Median age at
diagnosis did not signiﬁcantly diﬀer between genders,
either in parents (P=0.42) or in descendants (P=0.23).
The overall median age at diagnosis was 43 years
(IQR=14), with incidence ages ranging from 18 to
62 years (Fig. 1a). Taking the median of the paired age
diﬀerences, descendants (39 years, IQR=12) were
diagnosed 8 years earlier than their parents (47 years,
IQR=10.0), the diﬀerence being statistically signiﬁcant
(paired Wilcoxon test, P<0.0001), with 76%, 9% and
15% of descendants being diagnosed at an earlier, same,
and later age, respectively (Table 1). Moreover, the
paired age diﬀerence was more marked if the parents
had developed CRC at a later age (Fig. 1b).
A comparison of the median age at diagnosis
according to the gene mutated revealed that descendants
with an MLH1 germ-line mutation were diagnosed sta-
tistically signiﬁcantly earlier than those with an MSH2
mutation (38 vs. 43.5 years, P < 0.05) in contrast to
parents (47 vs. 48 years, P=0.91). Similarly, PCPs with
a MLH1 mutation displayed a signiﬁcant median of the
paired age diﬀerence (P<0.01). The median of the
paired age diﬀerence in MSH2 PCPs with CRC did not
reach statistical signiﬁcance, possibly because of the
small sample size (n=14; P=0.12; Table 1).
When subdividing PCPs according to parental
transmission, sons and daughters who inherited the
disease allele from their father showed a signiﬁcantly
increased median age diﬀerence of 11 years (P<0.001)
compared with 4 years in children who had inherited the
germline mutation from the mother (P<0.01; Table 2).
Importantly, median age at diagnosis did not signiﬁ-
cantly diﬀer between mothers (45 years, IQR=14) and
fathers (47 years, IQR=10; P=0.5).
In order to test whether the observation of apparent
anticipation could reﬂect a birth cohort bias of ascer-
tainment, we grouped the PCPs according to the birth
year of the children and created three birth cohorts: (1)
those born before 1916 (n=9), (2) those born between
1916 and 1936 (n=20) and (3) those born after 1936
(n=24). As depicted in Table 3, the median of the paired
age diﬀerence remained statistically signiﬁcant in the
ﬁrst (15 years; P=0.01) and third cohort (9 years;
P=0.001). In the second cohort, the median age diﬀer-
ence amounted to 5 years but just missed statistical
signiﬁcance (two-sided P=0.06).
Discussion
In this study, we provide signiﬁcant evidence for genetic
anticipation in 55 PCPs coming from 21 Swiss HNPCC
kindreds with characterised MLH1 or MSH2 germline
mutations. Compared with the parents, descendants
developed CRC 8 years earlier, in particular if the par-
ents had developed cancer at a later age.
Other than the initial observation by Warthin
(1925), only four studies deal in detail with the occur-
rence of genetic anticipation in HNPCC, i.e. the pro-
gressive decrease in age of onset of CRC in successive
generations. Although three investigations have ob-
Table 1 Median age (years) at diagnosis of colorectal cancer (CRC) in parents and descendants, and according to MMR germline
mutation. P-values are given for the respective diﬀerence in age at diagnosis between parents and descendants (IQR interquartile range
and n the number of PCPs)
Subjects Overall MLH1 (n=41) MSH2 (n=14)
Age IQR Range Age IQR Range Age IQR Range
Parents (P) 47 10 22–62 47 11 22–62 48 7 34–60
Descendants (D) 39 12 18–58 38 10 18–55 44 16 29–58
Diﬀerence P-D 8 15 14 to 30 11 15 14 to 30 2 8 12 to 20
n 55 41 14
P <0.0001 <0.001 0.12
Table 2 Median of the paired age diﬀerence according to the sex of
the transmitting parent
Transmission n Age diﬀerence
(years)
IQR Range
Mother to child (P<0.01) 19 4 13.75 13 to 25
Mother to daughter 7 3 11.75 13 to 20
Mother to son 12 4.5 14.5 10 to 25
Father to child (P<0.001) 34 11 17 14 to 30
Father to daughter 13 11 14 14 to 17
Father to son 21 7 18.5 7 to 30
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served anticipation in HNPCC kindreds fulﬁlling the
Amsterdam Criteria I (ACI), they cannot be directly
compared with our study, since (1) no statistical tests
were applied, or (2) investigations were carried out ei-
ther before the actual discovery of the genes responsi-
ble (Menko et al. 1993; Vasen et al. 1994) or
afterwards, but without molecular genetic characteri-
sation (Rodriguez-Bigas et al. 1996). The fourth study
by Tsai et al. (1997) analysed a total of 67 ACI-positive
PCPs (38 families) with MSH2 and MLH1 germline
mutations characterised in 14 pairs (7 families) of them.
However, they could not detect any diﬀerence in mean
age at diagnosis between generations in any of the
subgroups analysed. This apparent contradiction to our
ﬁndings could be attributable to the small sample size
(14, compared with 55 PCPs in our study) leading to a
type II error (failure to reject the null hypothesis). In
addition, the comparison might be hampered by dif-
ferences in the way in which data were collected and
the time window analysed.
In contrast to the ﬁndings by Tsai et al. (1997), a
possible birth cohort bias of ascertainment could not be
conﬁrmed in our study group (Table 3): the median of
the paired age diﬀerence remained statistically signiﬁ-
cant in the youngest and oldest birth cohort (9 years,
P<0.001, and 15 years, P<0.01, respectively), and just
failed to reach signiﬁcance in the middle birth cohort
(5 years, P=0.06). On the other hand, PCPs with can-
cers other than CRC (n=36), which were excluded from
the original study, revealed a clear birth cohort eﬀect
(data not shown).
Intriguingly, genetic anticipation in our study popu-
lation was more pronounced if the disease allele was
transmitted through the father than through the mother
(9.5 vs. 4 years paired median age diﬀerence, respec-
tively; Table 2). This ﬁnding does not appear to be
attributable to diﬀerences in median age at diagnosis
between fathers and mothers, as this was similar in both
parental groups (47 vs. 45 years; P=0.5). Green et al.
(2002) have observed similar parent-of-origin eﬀects in a
large HNPCC kindred with a founder mutation in
MSH2: females who inherited the mutation from their
father had an increased risk of developing CRC and of
dying of cancer compared with females carrying a
maternally transmitted mutation. It remains to be seen,
however, whether this apparent parental transmission
eﬀect in our study group is merely the result of ascer-
tainment bias or may actually reﬂect a true biological
phenomenon. If so, it is tempting to speculate that this
eﬀect is related to diﬀerences in male and female
gametogenesis, in particular given the greater number of
cell divisions during spermatogenesis and continuous
replication throughout adulthood. Given the data
implicatingMLH1 in the meiotic recombination process
(Eaker et al. 2002; Wang et al. 1999) and in analogy to
genetic anticipation observed in trinucleotide repeat
disorders such as Huntington’s disease (Quinn and
Schrag 1998), MMR (haplo) insuﬃciency in the germ-
line could be hypothesised to lead to anticipation via low
level repeat instability.
Despite the evidence for genetic anticipation pre-
sented here, there are several caveats to this retrospective
study. First of all, we cannot exclude an ascertainment
bias, since our study population represents a highly se-
lected group of patients. In particular, selection bias
might have resulted from either under-representation of
‘‘younger parent–older child’’ pairs in which the parent
had died before producing a ‘‘complete’’ family or from
selection for descendants with early onset CRC. Fur-
thermore, the signiﬁcant diﬀerence in age at diagnosis of
CRC observed between the generations could (1) reﬂect
changes in environmental factors such as dietary and life
style habits, (2) be attributable, at least in part, to earlier
and better diagnosis progressively over time and/or (3)
greater awareness/anxiety in descendants. It is therefore
mandatory that these ﬁndings are conﬁrmed in larger,
ideally prospective studies of HNPCC kindreds. These
could also allow an assessment of the occurrence of
genetic anticipation for other HNPCC related tumours,
particularly endometrial cancer.
In summary, we have presented signiﬁcant evidence
that genetic anticipation occurs in HNPCC families
harbouring MMR gene mutations, with descendants
being diagnosed with CRC 8 years earlier than their
parents. Intriguingly, this eﬀect seems to be more pro-
nounced if the disease allele is transmitted through the
father. If our ﬁndings concerning genetic anticipation in
general and paternal transmission in particular are
conﬁrmed, they may have important implications for the
genetic counselling and clinical management of MMR
gene mutation carriers and their oﬀspring.
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